Drug Trial Radar · NCT02541383
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Apr 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,085
Actual
Start
Sep 2015
Primary completion
Aug 27, 2020
Study completion Sep 1, 2023
Sponsor
- Lead sponsor
- Intergroupe Francophone du MyelomeResearch network
- Sponsor type
- Research network
- Collaborators
- HOVON - Dutch Haemato-Oncology Association; Janssen Research & Development, LLC
- First posted
- Sep 4, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free survival after daratumumab maintenance therapy in transplant eligible participants with previously untreated Multiple Myeloma.
Conditions
- Multiple Myeloma
Interventions
Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)Drug
Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation
Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumabDrug
Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation
DaratumumabDrug
Daratumumab 16mg/kg every 8 weeks for 2 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- Post-Consolidation Stringent Complete Response (sCR) RateTime frame: At day 100 post Autologous Stem Cell Transplant (ASCT), up to 114 days post ASCT
- Progression Free Survival (PFS) Post Completion of Maintenance TherapyTime frame: From the date of second randomization to either progressive disease or death which ever occurred first, with a median follow-up time of 35.4 months (cut-off for analysis was 26 months after the last rando 2 date).
Locations
107 sites in 3 countries. Site status is shown where the registry gives one.
BE-Antwerp-ZNA Stuivenberg
Antwerp, Belgium
AZ St Jan Brugge Oostende AV
Bruges, Belgium
Institut Jules Bordet
Brussels, Belgium
UCL Saint-Luc
Brussels, Belgium
UZ Brussel
Brussels, Belgium
GHDC
Charleroi, Belgium
UZ Gent
Ghent, Belgium
CH Jolimont
La Louvière, Belgium
University Hospital Leuven
Leuven, Belgium
Domaine Universitaire du Sart Tilman
Liège, Belgium
AZ Delta
Roeselare, Belgium
AZ Turnhout
Turnhout, Belgium
UCL Mont-Godinne
Yvoir, Belgium
CHU Amiens Sud
Amiens, France
CHRU-Hôpital du Bocage
Angers, France
Centre Hospitalier d'Argenteuil Victor Dupouy
Argenteuil, France
Centre Hospitalier H.Duffaut
Avignon, France
Centre hospitalier de la Côte Basque
Bayonne, France
Hôpital Jean Minjoz
Besançon, France
Hôpital Avicenne
Bobigny, France
Polyclinique Bordeaux Nord Acquitaine
Bordeaux, France
Hôpital de Fleyriat
Bourg-en-Bresse, France
CHRU Brest - Hôpital A. Morvan
Brest, France
CHU Caen - Côte de Nacre
Caen, France
Clinique du Parc
Castelnau-le-Lez, France
CH René Dubos
Cergy-Pontoise, France
Hôpital Privé Sévigné
Cesson-Sévigné, France
Centre Hospitalier William Morey
Chalon-sur-Saône, France
CH Chambéry
Chambéry, France
Hôpital d'Instruction des Armées Percy
Clamart, France
CHU d'Estaing
Clermont-Ferrand, France
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France
CHU Henri Mondor
Créteil, France
CHRU Dijon - Hôpital des Enfants
Dijon, France
Centre Hospitalier Général
Dunkirk, France
CHRU Hôpital A. Michallon
Grenoble, France
CHD Vendée
La Roche-sur-Yon, France
CHV André Mignot - Université de Versailles
Le Chesnay, France
CH de Chartres - Hôpital Louis Pasteur
Le Coudray, France
Centre Hospitalier
Le Mans, France
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.